Oral Wegovy Pill (25 mg): What the FDA Approval Means

For years, the FDA-approved semaglutide weight-management option was a weekly injection. On December 22, 2025, that changed: the FDA approved a once-daily oral semaglutide 25 mg tablet — branded as the Wegovy pill — for chronic weight management¹. It is the first oral GLP-1 medicine approved for obesity in the United States¹. If you have already heard of "the semaglutide pill," though, you may be picturing Rybelsus, which is a different product entirely. Here is what the new pill is, what its trial actually showed, and why it is not the same thing as Rybelsus.

What the FDA actually approved

The new approval is for oral semaglutide at a 25 mg once-daily dose, marketed under the Wegovy brand, as an adjunct to a reduced-calorie diet and increased physical activity for adults with obesity, or overweight with at least one weight-related condition. It is also approved to reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight.⁵ The tablet and injection share an active ingredient but have different dosing schedules; 25 mg daily is the tablet maintenance dose, not the starting dose.⁵

That distinction matters because semaglutide already existed in pill form before this. Rybelsus, approved back in 2019, is oral semaglutide too — but it is approved for glucose control and cardiovascular risk reduction in eligible adults with type 2 diabetes, has a 14 mg maximum for the Rybelsus formulation, and is not approved for weight management.² The current combined label also lists distinct Ozempic tablets at 1.5, 4 and 9 mg; these are not substitutable milligram for milligram with Rybelsus.² We unpack that product in detail in Rybelsus (oral semaglutide): does the pill work for weight loss?. Oral Wegovy has its own weight-management and cardiovascular indications and a dedicated obesity trial. Do not identify a product solely by the words “oral semaglutide.”

What OASIS-4 showed

The approval rested largely on OASIS-4, a phase 3 trial published in the New England Journal of Medicine in 2025³. It randomized 307 adults with obesity, or overweight with weight-related complications — and notably without diabetes — to once-daily oral semaglutide 25 mg or placebo over 64 weeks (which included a roughly 12-week dose-escalation period)³.

The headline number you will see quoted is 16.6% average weight loss. That figure describes the effect when participants stayed on treatment as intended, versus about 2.7% on placebo^1,3. Roughly one in three people on the drug lost 20% or more of their body weight¹. The label’s intention-to-treat analysis, which includes the effects of stopping assigned treatment, reports 13.6% average loss versus 2.4% with placebo.⁵ These are different analysis approaches from the same trial, not competing promises or a head-to-head comparison with injections.

A few honest caveats keep that number in proportion. OASIS-4 was a relatively small trial (307 people) over a defined window, and the 16.6% reflects on-treatment adherence rather than a guarantee for everyone who fills a prescription. As with all GLP-1 medicines, results depend on actually reaching and tolerating the target dose, and weight tends to return when the drug is stopped — a pattern we cover in what happens if you stop semaglutide?.

Why the 25 mg pill ≠ the 14 mg Rybelsus pill

This is the single most common point of confusion, so it is worth being precise. Both Rybelsus and oral Wegovy are oral semaglutide. The reason they behave so differently comes down to dose and absorption.

Semaglutide is a peptide, and the stomach normally destroys peptides. Oral semaglutide gets around this with an absorption enhancer, but only a small, variable fraction of each tablet is actually absorbed — which is why oral doses have to be far larger than the injection to reach comparable blood levels. Rybelsus is capped at 14 mg, a diabetes dose that produces only modest weight loss². Oral Wegovy is 25 mg with a dedicated obesity trial behind it. So the dramatic OASIS-4 numbers belong to the 25 mg obesity product — not to the 14 mg Rybelsus tablet a pharmacy dispenses for diabetes. (For more on why swallowed semaglutide is finicky dose-for-dose, see oral vs injectable semaglutide.)

The dosing rules are still strict

The absorption problem also dictates how the pill must be taken, and these rules are not optional fine print. The Wegovy label requires a morning empty-stomach dose with no more than four ounces of water, followed by at least 30 minutes before food, other drinks or other oral medicines; swallow it whole.⁵ The label escalates from 1.5 mg to 4 mg to 9 mg, with 25 mg maintenance beginning on day 91 if tolerated.⁵ Breaking these rules — taking it with food or extra water — meaningfully lowers how much drug is absorbed, which can blunt the very effect you are paying for. A pill is more convenient than a needle, but only if the timing discipline is followed. If that routine is a dealbreaker, Foundayo, Lilly's GLP-1 pill with no food or water rules, is the alternative to weigh.

For a usable schedule, see the oral semaglutide morning routine. If another fasting medicine is involved, semaglutide and levothyroxine explains why taking all morning pills together can be a problem.

Side effects and cautions: the same GLP-1 family

Because it is the same molecule acting on the same GLP-1 receptors, oral Wegovy shares common side-effect categories with injectable semaglutide, but adverse-event rates and formulation-specific warnings are not identical — most commonly nausea, vomiting, diarrhea, and constipation, which can be most noticeable during dose escalation and may improve over time.⁵ It also carries the same class-level cautions, including the boxed warning about thyroid C-cell tumors seen in rodents and a contraindication in people with a personal or family history of medullary thyroid carcinoma or MEN2.⁵ There is also a separately tracked, very rare eye-nerve signal (NAION) now noted by regulators for semaglutide medicines, which we cover in semaglutide and NAION (vision risk). This is a prescription-only medicine, not a casual supplement. For managing the gut symptoms through titration, see semaglutide dosing & side effects.

Breastfeeding is one important formulation difference: the label advises against breastfeeding during tablet treatment because of the oral absorption enhancer SNAC. The injection has a different benefit-risk discussion. See semaglutide and breastfeeding for the small human study and its limits.⁵

So what does the approval actually mean for you?

Practically, it means there is now a needle-free way to get obesity-dose semaglutide with real trial evidence behind it — a meaningful option for people who cannot or will not inject. But it does not mean the pill is automatically the right choice. The injectable Wegovy still has the larger and longer evidence base, and the daily empty-stomach routine of the oral version is a real commitment. Cost and coverage will also shape the decision, since GLP-1 medicines are expensive and insurance for obesity treatment is uneven — the manufacturer sells the tablet direct at a published cash price through its own NovoCare mail-order pharmacy, and Sesame Care lists it on a pick-your-provider marketplace with a platform fee billed alongside it, and Hers offers it to women through a monthly membership billed separately from the pill. We break down the tablet's pricing specifically in Wegovy pill cost: with vs without insurance, and cover the injection in Wegovy cost & savings and does insurance cover Wegovy and Ozempic?. (And note that the cheap "compounded semaglutide" route that filled the gap during the shortage has largely closed — see is compounded semaglutide still legal in 2026?.) For how the semaglutide options stack up overall, see our best semaglutide guide, and for the full picture of how the drug works, our pillar, Semaglutide: how it works, results & side effects.